Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.130 -0.060 (-5.04%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

June 27, 2024

Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

June 25, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M

June 18, 2024

Via Investor Brand Network

Topics Artificial Intelligence

Gain Therapeutics: Q4 Earnings Insights ↗

March 26, 2024

Via Benzinga

S&P 500 Edges Lower; RH Shares Plunge After Q1 Results ↗

June 14, 2024

Via Benzinga

Topics Stocks

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 14, 2024

Via Benzinga

Gold Gains 1%; US Consumer Sentiment Falls In June ↗

June 14, 2024

Via Benzinga

Dear ARM Stock Fans, Mark Your Calendars for June 24 ↗

June 14, 2024

Arm stock is up on Friday and is preparing for a catalyst later this month when it replaces Sirius XM on the Nasdaq 100.

Via InvestorPlace

Dow Tumbles Over 200 Points; Adobe Earnings Top Views ↗

June 14, 2024

Via Benzinga

Topics Stocks

Why Is Gain Therapeutics (GANX) Stock Down 25% Today? ↗

June 14, 2024

Gain Therapeutics stock is down on Friday after the company priced an $11 million public offering for roughly 7 million shares of GANX.

Via InvestorPlace

Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

June 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 14, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 14, 2024

Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!

Via InvestorPlace

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

June 13, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

June 13, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 30, 2024

Via Benzinga

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 30, 2024

New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease

From Gain Therapeutics, Inc.

Via GlobeNewswire

GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024 ↗

May 14, 2024

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

May 14, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

April 24, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 08, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying ↗

April 02, 2024

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

April 01, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023 ↗

March 26, 2024

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

March 26, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics to Present at Public Ventures Discovery Day

March 15, 2024

Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb...

From Gain Therapeutics, Inc.

Via GlobeNewswire

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

March 05, 2024

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction

From Gain Therapeutics, Inc.

Via GlobeNewswire

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease ↗

March 05, 2024

Gain Therapeutics' GBA1 Parkinson's disease focused GT-02287's mechanism of action, tackling GCase misfolding to enhance lysosomal activity.

Via Benzinga

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

February 27, 2024

From Gain Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.